Wednesday, February 12, 2025 The recently opened ALC8 treatment trial will be testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia (AML). Researchers want to compare the usual treatment for high-risk AML with four different combinations of treatment. “The goal of this clinical trial is to identify the treatment regimen that achieves the best response rate in patients with newly diagnosed untreated high-risk AML,” says Dr. Guillaume Richard-Carpentier, hematologist in the leukemia group at the Princess Margaret Cancer Centre, is the ALC8 study champion at CCTG.Treatment plans for AML often involve several phases but this study is focused on the first phase of treatment. These new treatment options could improve the success of further phases of treatment, but it is not clear if they offer better results than the usual treatment. "This trial will give high-risk AML patients with poor prognosis and their care providers another option for treatment and aims to improve their survival rate as well as their quality of life during and after treatment," says Melissa Coombs, CCTG Patient Representative.This phase II trial is part of a larger research study called myeloMATCH a master screening and re-assessment protocol which uses biomarker testing to match AML and MDS patients to clinical trials.ALC8 patient information page >ALC8 members trial page > Dr Lois Shepherd, CCTG Senior Investigator Melissa Coombs, CCTG Patient Representative Dr. Guillaume Richard-Carpentier, ALC8 Study Champion
